Vimarsana
Biggest News Aggregation in the World

Page 2 - Realtime Dynamix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Realtime Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Realtime Dynamix Today - Breaking & Trending Today

First-to-Market Edge for Apellis's Syfovre in Geographic - Vimarsana News

First-to-Market Edge for Apellis's Syfovre in Geographic

Prospects for Syfovre uptake and trust in Apellis take a plunge following reports of intraocular inflammation, according to Spherix Global Insights...

Approximately One-Year Post-Launch, AbbVie's Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights - Vimarsana News

Approximately One-Year Post-Launch, AbbVie's Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights

/PRNewswire/ -- In March of 2022, the FDA approved AbbVie's JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis...

At Eighteen Months Post-Launch, Impel's Trudhesa Has Struggled to Keep Up with Pfizer's Nurtec ODT and AbbVie's Ubrelvy, According to Spherix Global Insights - Vimarsana News

At Eighteen Months Post-Launch, Impel's Trudhesa Has Struggled to Keep Up with Pfizer's Nurtec ODT and AbbVie's Ubrelvy, According to Spherix Global Insights

/PRNewswire/ -- Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study...

Genentech's Vabysmo Well-Received Amongst Ophthalmologists, but Use Continues to Lag the Competition, According to Spherix Global Insights - Vimarsana News

Genentech's Vabysmo Well-Received Amongst Ophthalmologists, but Use Continues to Lag the Competition, According to Spherix Global Insights

/PRNewswire/ -- According to Spherix Global Insights' Launch Dynamix™: Vabysmo service, to no surprise, Regeneron's Eylea continues to lead the charge in both...

Familiarity with GSK's Jesduvroq® (daprodustat) Likely to Be Strong Driver of Adoption in Dialysis, According to Spherix Global Insights - Vimarsana News

Familiarity with GSK's Jesduvroq® (daprodustat) Likely to Be Strong Driver of Adoption in Dialysis, According to Spherix Global Insights

/PRNewswire/ -- In the 32nd wave of ongoing tracking of the U.S. Renal Anemia market, Spherix surveyed 207 US nephrologists about overall patient management...